Compare FLGT & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLGT | ESPR |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.4M | 898.5M |
| IPO Year | 2016 | 2013 |
| Metric | FLGT | ESPR |
|---|---|---|
| Price | $23.06 | $3.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $28.33 | $6.67 |
| AVG Volume (30 Days) | 196.7K | ★ 5.3M |
| Earning Date | 02-27-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $315,549,000.00 | $303,802,000.00 |
| Revenue This Year | $16.84 | $27.49 |
| Revenue Next Year | $9.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.61 | 2.83 |
| 52 Week Low | $14.57 | $0.69 |
| 52 Week High | $31.04 | $4.18 |
| Indicator | FLGT | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 22.58 | 48.87 |
| Support Level | $22.76 | $3.16 |
| Resistance Level | $26.74 | $3.64 |
| Average True Range (ATR) | 0.82 | 0.21 |
| MACD | -0.47 | 0.01 |
| Stochastic Oscillator | 5.13 | 61.94 |
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.